

In the Claims

Please amend claim 21, cancel claims 55, 69 and 74-75; and add new claims 104-110 as follows: (All the pending claims are recited below for the Examiner's convenience).

21. (Amended) A peptide analogue of a parent peptide, wherein the parent peptide is a peptide of the AIDS virus (Human immunodeficiency Virus Type I, HIV1), said parent peptide being derived from an exogenous protein or an endogenous protein, wherein said parent peptide interacts with molecules of the MHC in the context of a pathological condition involving a cell mediated immune response in an animal, wherein:

(a) at least one peptide bond (-CO-NH-) of the parent peptide chain is modified, and wherein the modifications do not comprise a retro type modification or a retro-inverso type modification; or

(b) at least one amino acid of the parent peptide chain is substituted with a non-protein-generating amino acid; or

(c) at least one peptide bond (-CO-NH-) of the parent peptide chain is modified and at least one amino acid of said parent peptide chain is substituted with a non-protein-generating amino acid.

56. (Amended) The peptide analogue according to claim 21, wherein the parent peptide is the peptide NEF 84-92 or the peptide GAG 77-85.

57. The peptide analogue according to claim 56, wherein at least one of the peptide bonds (-CO-NH-) of the parent peptide is modified, with the exception of modifications of the retro or retro-inverso type.

58. The peptide analogue according to claim 21, wherein said peptide analogue is an analogue of NEF84-92 selected from the group consisting of the peptides NEFRD1-8 as follows:

NEFRD1	AΨ(CH ₂ -NH)VDLSHFLK
NEFRD2	AVΨ(CH ₂ -NH)DLSSHFLK
NEFRD3	AVDΨ(CH ₂ -NH)LSHFLK
NEFRD4	AVDLΨ(CH ₂ -NH)SHFLK
NEFRD5	AVDLSΨ(CH ₂ -NH)HFLK

NEFRD6	AVDLSHΨ(CH ₂ -NH)FLK
NEFRD7	AVDLSHFΨ(CH ₂ -NH)LK
NEFRD8	AVDLSHFLΨ(CH ₂ -NH)K.

59. The peptide analogue according to claim 21, wherein said peptide analogue is an analogue of NEF84-92 selected from the group consisting of the peptides NEFHEA1-8 as follows:

NEFHEA1	AΨ(CHOH-NH)VDLSHFLLK
ONEFHEA2	AVΨ(CHOH-NH)DLSHFLLK
NEFHEA3	AVDΨ(CHOH-NH)LSHFLLK
NEFHEA4	AVDLΨ(CHOH-NH)SHFLLK
NEFHEA5	AVDLSΨ(CHOH-NH)HFLK
NEFHEA6	AVDLSHΨ(CHOH-NH)FLK
NEFHEA7	AVDLSHFΨ(CHOH-NH)LK
NEFHEA8	AVDLSHFLΨ(CHOH-NH)K.

60. The peptide analogue according to claim 21, wherein said peptide analogue is an analogue of GAG 77-85 selected from the group consisting of the peptides GAGRD1-8 as follows:

GAGRD1	SΨ(CH ₂ -NH)LYNTVATL
GAGRD2	SLΨ(CH ₂ -NH)YNTVATL
GAGRD3	SLYΨ(CH ₂ -NH)NTVATL
GAGRD4	SLYNΨ(CH ₂ -NH)TVATL
GAGRD5	SLYNTΨ(CH ₂ -NH)VATL
GAGRD6	SLYNTVΨ(CH ₂ -NH)ATL
GAGRD7	SLYNTVAΨ(CH ₂ -NH)TL
GAGRD8	SLYNTVATΨ(CH ₂ -NH)L.

104. (New) A vaccine composition for the prevention or treatment of a condition associated with a cell mediated immune response involving cytotoxic T lymphocytes, wherein a parent peptide interacts with molecules of the MHC in the context of a pathological condition involving a cell mediated immune response in an animal, wherein the parent peptide is a peptide from human immunodeficiency virus, HIV1 or HIV2 and said parent peptide is an agonist or a partial agonist of a receptor which recognizes the antigen of the cytotoxic T

lymphocytes; said vaccine comprising a peptide analogue of the parent peptide, wherein:

(a) at least one peptide bond (-CO-NH-) of the parent peptide chain is modified, and wherein the modifications do not comprise a retro type modification or a retro-inverso type modification; or

(b) at least one amino acid of the parent peptide chain is substituted with a non-protein-generating amino acid; or

(c) at least one peptide bond (-CO-NH-) of the parent peptide chain is modified and at least one amino acid of said parent peptide chain is substituted with a non-protein-generating amino acid;

and a pharmaceutically acceptable vehicle.

105. (New) The vaccine composition of claim 104, wherein the parent peptide of the human immunodeficiency virus, HIV1 or HIV2 comprises a NEF or GAG sequence.

106. (New) The vaccine composition according to claim 105, wherein the parent peptide is the peptide NEF 84-92 or the peptide GAG 77-85.

107. (New) The vaccine composition according to claim 104, wherein at least one of the peptide bonds (-CO-NH-) of the parent peptide is modified, with the exception of modifications of the retro or retro-inverso type.

108. (New) The vaccine composition according to claim 105, wherein said peptide analogue is an analogue of NEF84-92 selected from the group consisting of the peptides NEFRD1-8 as follows:

NEFRD1	AΨ(CH ₂ -NH)VDLSHFLK
NEFRD2	AVΨ(CH ₂ -NH)DLSSHFLK
NEFRD3	AVDΨ(CH ₂ -NH)LSHFLK
NEFRD4	AVDLΨ(CH ₂ -NH)SHFLK
NEFRD5	AVDLSΨ(CH ₂ -NH)HFLK
NEFRD6	AVDLSSHΨ(CH ₂ -NH)FLK
NEFRD7	AVDLSHFΨ(CH ₂ -NH)LK
NEFRD8	AVDLSHFLΨ(CH ₂ -NH)K.

109. (New) The vaccine composition according to claim 105, wherein said peptide analogue is an analogue of NEF84-92 selected from the group consisting of the peptides NEFHEA1-8 as follows:

NEFHEA 1	A Ψ (CHOH-NH) V D L S H F L K
0 NEFHEA 2	A V Ψ (CHOH-NH) D L S H F L K
NEFHEA 3	A V D Ψ (CHOH-NH) L S H F L K
NEFHEA 4	A V D L Ψ (CHOH-NH) S H F L K
NEFHEA 5	A V D L S Ψ (CHOH-NH) H F L K
NEFHEA 6	A V D L S H Ψ (CHOH-NH) F L K
NEFHEA 7	A V D L S H F Ψ (CHOH-NH) L K
NEFHEA 8	A V D L S H F L Ψ (CHOH-NH) K .

110. (New) The vaccine composition according to claim 105, wherein said peptide analogue is an analogue of GAG 77-85 selected from the group consisting of the peptides GAGRD1-8 as follows:

GAGRD 1	S Ψ (CH ₂ -NH) L Y N T V A T L
GAGRD 2	S L Ψ (CH ₂ -NH) Y N T V A T L
GAGRD 3	S L Y Ψ (CH ₂ -NH) N T V A T L
GAGRD 4	S L Y N Ψ (CH ₂ -NH) T V A T L
GAGRD 5	S L Y N T Ψ (CH ₂ -NH) V A T L
GAGRD 6	S L Y N T V Ψ (CH ₂ -NH) A T L
GAGRD 7	S L Y N T V A Ψ (CH ₂ -NH) T L
GAGRD 8	S L Y N T V A T Ψ (CH ₂ -NH) L .

23
Covet